Underwood International College

Assistant Professor of Bio-Convergence

• Assistant Professor Adjunct in the section of Endocrinology, Internal Medicine, Yale University, USA (2022-2023)
• Postdoctoral Associate, Yale University, USA
• Ph.D. in Immunobiology, Yale University, USA
• Research Associate, National Cancer Center, Korea
• M.S. in Biotechnology, Yonsei University, Korea
• B.S. in Biotechnology, Yonsei University, Korea

Education

• Ph.D. in Immunobiology, Yale University, 2019
• M.S. in Biotechnology, Yonsei University, 2008
• B.S. in Biotechnology, Yonsei University, 2006

Courses and Current Research Areas

Courses

• Immunology
• Molecular Biology of Cancer
• Junior Independent Study
• General Biology

Current Research Areas

• Cancer Immunology
• Organoid research
• Lactation Immunology

Selected Publications

1. Shin JH*, Jeong J, Maher SE, Lee HW, Lim J and Bothwell AL. Colon cancer cells acquire immune regulatory molecules from tumor-infiltrating lymphocytes by trogocytosis. PNAS 118 (48), 2021

* First and Corresponding author

2. Shin JH, Jeong J, Choi J, Lim J, Dinesh RK, Braverman J, Hong JY, Maher SE, Vesely MA, Kim WJ, Koo JH, Tang W, Wu D, Blackburn HN, Xicola RM, Llor X, Yilmaz O, Choi JM and Bothwell AL. Dickkopf-2 regulates the stem cell marker LGR5 in colorectal cancer via HNF4α1. iScience 24 (5), 102411, 2021

3. Jeong J, Shin JH**, Li W, Hong JY, Lim J, Hwang JY, Chung JJ, Yan Q, Choi J, Wysolmerski J. MAL2 mediates the formation of stable HER2 signaling complexes within lipid raft-rich membrane protrusions in breast cancer cells. Cell Reports 37, 110160, 2021

** Co-first author

4. Park MH, Shin JH***, Bothwell AL, Chae WJ. Dickkopf proteins in pathological inflammatory diseases. Journal of Leukocyte Biology 10 Dec. 2021

*** Co-first author

5. Shin JH, Park HB, Choi K. Enhanced anti-tumor reactivity of cytotoxic T lymphocytes expressing PD-1 decoy. Immune Network 16:134-139, 2016

6. Chae WJ, EhrlichAK, ChanPY, TeixeiraAM, HenegariuO, HaoL, ShinJH, ParkJH, TangWH, KimST, MaherSE, Goldsmith-PestanaK, Shan P, HwaJ, Lee PJ, KrauseDS, RothlinCV, McMahon-PrattD, Bothwell AL. The Wnt antagonist Dickkopf-1 promotes pathological type 2 inflammation. Immunity 44: 246-258, 2016

7. Oh YM, Park HB, Shin JH, Lee JE, Park HY, Kho DH, Lee JS, Choi H, Okuda T, Kokame K, Miyata T, Powell JD, Kim IH, Lee SH, Schwartz RH, Choi K. Ndrg1 is a T-cell clonal anergy factor negatively regulated by CD28 costimulation and interleukin-2. Nature Communications 6: 8698, 2015

8. Lim S, Kim WJ, Kim YH, Lee S, Koo JH, Lee JA, Yoon H, Kim DH, Park HJ, Kim HM, Lee HG, Kim JY, Lee JU, Shin JH, Kim LK, Doh J, Kim H, Lee SK, Bothwell AL, Suh M, Choi JM. dNP2 is a blood–brain barrier-permeable peptide enabling ctCTLA-4 protein delivery to ameliorate experimental autoimmune encephalomyelitis. Nature Communications 6: 8244, 2015

9. Shin SP, Seo HH, Shin JH, Park HB, Lim DP, Eom HS, Bae YS, Kim IH, Choi K, Lee SJ. Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response. Molecular Therapy 21 (3): 688-95, 2013

10. Shin JH, Park HB, Oh YM, Lim DP, Lee JE, Seo HH, Lee SJ, Eom HS, Kim IH, Lee SH, Choi K. Positive conversion of negative signaling of CTLA4 potentiates anti-tumor efficacy of adoptive T cell therapy in murine tumor models. Blood 119 (24): 5678-87, 2012

11.Choi JM, Shin JH, Sohn MH, Harding MJ, Park JH, Tobiasova Z, Kim DY, Maher SE, Chae WJ, Park SH, Lee CG, Lee SK, Bothwell AL. Cell-permeable Foxp3 protein alleviates autoimmune disease associated with inflammatory bowel disease and allergic airway inflammation. PNAS 107 (43): 18575-80, 2010

12.Choi JM, Kim SH, Shin JH, Gibson T, Yoon BS, Lee DH, Lee SK, Bothwell AL, Lim JS, Lee SK. Transduction of the cytoplasmic domain of CTLA-4 inhibits TcR-specific activation signals and prevents collagen-induced arthritis PNAS 105 (50): 19875-80, 2008

Patents

1. Choi K, Shin JH, Lee SJ. “Mutant ctla4 gene transfected t cell and composition including same for anticancer immunotherapy,” US009688740B2, June 27, 2017.

2. Choi K, Shin JH. “Mutant CTLA4 gene modified T-cell and composition for anticancer immunotherapy comprising thereof,” KR101471647B1, December 11, 2014.